183 related articles for article (PubMed ID: 28670847)
21. A comparison of genetic risk score with family history for estimating prostate cancer risk.
Helfand BT
Asian J Androl; 2016; 18(4):515-9. PubMed ID: 27004541
[TBL] [Abstract][Full Text] [Related]
22. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
[TBL] [Abstract][Full Text] [Related]
23. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
24. Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia.
Rhie A; Son HY; Kwak SJ; Lee S; Kim DY; Lew BL; Sim WY; Seo JS; Kwon O; Kim JI; Jo SJ
PLoS One; 2019; 14(9):e0222533. PubMed ID: 31525235
[TBL] [Abstract][Full Text] [Related]
25. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
26. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
27. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trial.
Kattan MW; Earnshaw SR; McDade CL; Black LK; Andriole GL
Appl Health Econ Health Policy; 2011 Sep; 9(5):305-15. PubMed ID: 21875161
[TBL] [Abstract][Full Text] [Related]
29. Reclassification of genetic-based risk predictions as GWAS data accumulate.
Krier J; Barfield R; Green RC; Kraft P
Genome Med; 2016 Feb; 8(1):20. PubMed ID: 26884246
[TBL] [Abstract][Full Text] [Related]
30. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial.
Chen Z; Greenwood C; Isaacs WB; Foulkes WD; Sun J; Zheng SL; Condreay LD; Xu J
Carcinogenesis; 2013 Jun; 34(6):1260-4. PubMed ID: 23393222
[TBL] [Abstract][Full Text] [Related]
31. Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer.
Deng Y; Xie K; Logothetis CJ; Thompson TC; Kim J; Huang M; Chang DW; Gu J; Wu X; Ye Y
Carcinogenesis; 2020 Aug; 41(8):1057-1064. PubMed ID: 32215555
[TBL] [Abstract][Full Text] [Related]
32. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
33. Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer.
Cremers RG; Galesloot TE; Aben KK; van Oort IM; Vasen HF; Vermeulen SH; Kiemeney LA
Prostate; 2015 Apr; 75(5):474-83. PubMed ID: 25560306
[TBL] [Abstract][Full Text] [Related]
34. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
35. Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study.
Vidal AC; Howard LE; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Clin Cancer Res; 2015 Feb; 21(4):756-62. PubMed ID: 25520389
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer detection and dutasteride: utility and limitations of prostate-specific antigen in men with previous negative biopsies.
van Leeuwen PJ; Kölble K; Huland H; Hambrock T; Barentsz J; Schröder FH
Eur Urol; 2011 Feb; 59(2):183-90. PubMed ID: 21130560
[TBL] [Abstract][Full Text] [Related]
37. Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.
Andriole GL; Bostwick DG; Gomella LG; Marberger M; Montorsi F; Tammela TL; Tindall DJ; Fowler IL; Garges HP; Wilson TH; Castro R
Urology; 2014 Aug; 84(2):393-9. PubMed ID: 24916669
[TBL] [Abstract][Full Text] [Related]
38. Concept and benchmarks for assessing narrow-sense validity of genetic risk score values.
Yu H; Shi Z; Wu Y; Wang CH; Lin X; Perschon C; Isaacs WB; Helfand BT; Lilly Zheng S; Duggan D; Mo Z; Lu D; Xu J
Prostate; 2019 Jul; 79(10):1099-1105. PubMed ID: 31037745
[TBL] [Abstract][Full Text] [Related]
39. Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density.
Bansal A; Arora A
J Endourol; 2017 Sep; 31(9):910-917. PubMed ID: 28650680
[TBL] [Abstract][Full Text] [Related]
40. Genetic factors influencing prostate cancer risk in Norwegian men.
Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
